ATSAF NEWS
seekingalpha.com
6d ago
Entravision: The Broadcaster That Quietly Became An Ad-Tech Company
Entravision Communications has transformed into a high-growth ad-tech platform, with ATS now driving the majority of revenue and profitability. ATS delivered 204% year-over-year revenue growth and 22% EBIT margins in Q1 2026, highlighting strong scalability and operating leverage. EVC trades at broadcasting multiples despite ad-tech-like growth and margins, suggesting further upside if ATS sustains momentum.
globenewswire.com
May 20
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new clinical and translational data presented at the American Thoracic Society (ATS) International Conference 2026 and the simultaneous publication in Clinical Immunology Communications 1 describing the use of sequential immunotherapy with MiNK's off-the-shelf iNKT cell therapy, agenT-797 and N-803, an IL-15 superagonist, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia.
prnewswire.com
May 18
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from IBI3002(IL-4Rα/TSLP), IBI3038(IGF-1R/IL-6), IBI3031(IGF-1R/TSHR) at the 2026 American Thoracic Society (ATS) International Conference, held in Orlando, Florida (US) from May 17–20 and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in Denver, Colorado (US) from May 3-7. ATS Presentation Title： IBI3002, A First-in-class Anti-IL-4Rα/TSLP Bispecific Antibody in Patients with Mild-To-Moderate Asthma: A Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase Ib Study Abstract Number：8579 Presentation Form: Poster Author：Dr. Yuanfang Ren, Innovent Biologics IBI3002 is a first-in-class bispecific antibody that simultaneously targets IL-4Rα and its upstream inflammatory cytokine―thymic stromal lymphopoietin (TSLP), a key cytokine involved in initiating and perpetuating the inflammatory response in the airways.
businesswire.com
May 18
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th.
globenewswire.com
May 18
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
globenewswire.com
May 18
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –
